Hired and Retired: Regulatory turbulence shakes the space
The end of the summer sees several leading companies, including Regeneron, Novartis, and Bayer, experience changes in their leadership.
The operations of the US Food and Drug Administration (FDA) have had a significant impact on the changes made during the past month, either due to regulatory action leading to companies removing their executives, or with moves from a governmental to an industry office.
The biopharmaceutical market saw a major company facing strong compliance burdens, leading to the removal of two of its executives.
